NICE TAs

12/10/2020

TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

12/10/2020

TA649:Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

01/10/2020

TA651: Naldemedine for treating opioid-induced constipation

02/09/2020

TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma

19/08/2020

NG101: Early and locally advanced breast cancer: diagnosis and management

19/08/2020

TA135: Pemetrexed for the treatment of malignant pleural mesothelioma

19/08/2020

TA116: Gemcitabine for the treatment of metastatic breast cancer

19/08/2020

TA124: Pemetrexed for the treatment of non-small-cell lung cancer

18/08/2020

TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

18/08/2020

TA134: Infliximab for the treatment of adults with psoriasis

18/08/2020

TA153: Entecavir for the treatment of chronic hepatitis B

18/08/2020

TA278: Omalizumab for treating severe persistent allergic asthma (replaced TA133)

18/08/2020

TA235: Mifamurtide for the treatment of osteosarcoma

18/08/2020

TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis

18/08/2020

TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia

18/08/2020

TA191: Capecitabine for the treatment of advanced gastric cancer

18/08/2020

TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (replaced TA175, terminated appraisal)

18/08/2020

TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

18/08/2020

TA247: Tocilizumab for the treatment of rheumatoid arthritis (this has been partially replaced by TA375 - only covers DMARDs, not TNF inhibitors)

18/08/2020

TA177: Alitretinoin for the treatment of severe chronic hand eczema